Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...

Hims & Hers Health, Inc. has shown significant improvement in key unit economics, positioning it among top-tier SaaS ...

Hims & Hers Health, Inc. (NYSE: HIMS) are trading lower Thursday. The U.S. Food and Drug Administration (FDA) issued a new decision regarding the status of tirzepatide injection shortages, which have ...

Hims & Hers Health, Inc. HIMS has emerged as a transformative player in the personalized healthcare market, showcasing robust ...

Hims & Hers Health (NYSE: HIMS) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a growth stock investors should watch, which Travis Hoium explains in ...

While Hims offers more options for sexual health and hair loss, Roman offers more options overall. Here’s our full breakdown of Hims vs. Roman for erectile dysfunction, hair loss, and more.

Hims & Hers (HIMS) is down -12.0%, or -$3.42 to $25.13. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks ...

Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

Hims & Hers Health Inc (NYSE:HIMS) stock is sitting out the broad market rally today, last seen down 8.4% to trade at $26.15. The personalized healthcare company -- a key player in the weight loss ...